Michael Murphy

Michael Murphy

For the last 25+ years, Michael Murphy has been an independent technology investment adviser, bringing professional research to individual investors. Through New World Investor, he shares his unique analysis of the MegaShifts — new technology trends and breakthroughs often still flying under the radar and the companies best positioned to reap the potentially staggering rewards.

Michael is a regular guest in the media with frequent appearances on CNBC and CNNfn and is often quoted in The Wall Street Journal, Barron’s and Money. He graduated with honors in economics from Harvard College and began his career in the computer industry’s infancy, first as COBOL programmer and mainframe systems analyst, then as the technology stock analyst for American Express in the 1970s and later as the CEO of two software companies where the lessons of this rapid-evolution world were forged in fire.

Recent Articles

2 Cancer Stocks to Approach With Caution

These companies are leading the pack in a new treatment for cancer, but investors should be wary.

Biotech Stock Zalicus Soaring in 2011

ZLCS stock is up over 40% in 2011 even after some profit-taking, and Michael Murphy expects the biotech to build on its run in the months ahead.

Cancer Drug Should Take Dendreon to $360

Dendreon Corp. (NASDAQ: DNDN) revolutionary cancer vaccine Provenge should make this biotech stock a huge winner.

Zalicus Proves It’s the Best ’11 Stock

Michael Murphy picked leading biotech stock Zalicus as his single best stock to buy in 2011. With +36% gains since Jan. 1, he was right.

Best Biotech Stock for 2011 – Zalicus (ZLCS)

Zalicus (NASDAQ:ZLCS) is Michael Murphy's favorite biotech stock picks for 2011.